CSF-1 drops demonstrate efficacy, safety in clinical studies for treatment of presbyopia

November 14, 2018

Conferences | AAO

Elad Kedar, CEO of Orasis Pharmaceuticals, provides a company update at OIS@AAO 2018 in Chicago.

Elad Kedar, CEO of Orasis Pharmaceuticals, provides a company update at OIS@AAO 2018 in Chicago.

Latest News

VIDEO: Eye trauma: Treatment trends and innovations

NYU Langone Health receives awards for quality, safety

Fulfilling expectations: A super highway to workability